Menu
The Pharmacopoeia of the People's Republic of China , commonly abbreviated as (or Zhongguo Yaodian ), is the official compendium of drugs, excipients, and traditional medicines. It is issued by the Chinese Pharmacopoeia Commission (ChPC) under the supervision of the National Medical Products Administration (NMPA).
The pharmacopoeia serves as the binding legal standard for: pharmacopoeia of the people 39-s republic of china pdf
Overview, Structure, and Digital Availability (PDF) Common Abbreviation: ChP Current Edition: 2020 Edition (2025 Edition forthcoming) The Pharmacopoeia of the People's Republic of China
: Unlike USP or EP, the ChP devotes an entire volume to TCM, establishing standards for identification, assay of marker compounds, and limits on pesticides, heavy metals, and aflatoxins. For example, the monograph for Radix Astragali (Huang Qi) specifies astragaloside IV content and HPLC fingerprinting. For example, the monograph for Radix Astragali (Huang
This edition became effective on December 30, 2020. It contains 5,911 monographs across four volumes. An official English translation has been available since March 2023. Volume Structure (2020 Edition) The pharmacopoeia is organized into four distinct volumes: Volume I: Traditional Chinese Medicine (TCM) monographs.